Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics ofdrug products.
Inspection Record
Qilu Pharmaceutical (Hainan) Co., Ltd. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The use of laboratory instruments not meeting established specifications was observed.
Equipment used in the manufacturing of drug products is not of adequate size.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Andrx Pharmaceuticals, Inc2015-07-24 · US FDASimilar to finding 2 The use of instruments and apparatus not meeting established specifications was observed.
- Macau-Union Pharmaceutical Limited2025-12-17 · US FDASimilar to finding 1 Control procedures are not established which monitor the output and validate the performance ofthose manufacturing processes that may be responsible for…
- Enemeez LLC2026-02-12 · US FDASimilar to finding 1 Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the…
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.